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1. Introduction 
The course and prognosis of patients infected with the human immunodeficiency virus 
(HIV) is changing dramatically following the introduction of highly active antiretroviral 
therapy (HAART), with increased patient survival and decreased morbidity (Mocroft et al, 
1998). 
Current therapy offers patients increased survival by making it more susceptible to certain 
comorbidities (Fang et al, 2007). Cardiovascular and renal diseases are the prototype of 
diseases whose prevalence increases progressively with the prolonged survival and aging 
(Braithwaite et al, 2005). On the other hand, besides specifically associated nephropathy or 
HIV coinfection with hepatitis C virus (HCV) with prolonged survival of the HIV-infected 
population, the spectrum of kidney disease in patients with HIV also reflects the growing 
burden of comorbid diabetes and hypertension and development chronic renal disease 
(Wyatt et al, 2007; Mocroft et al 2007; Szczech, 2004). 
The prevalence of chronic kidney disease in HIV patients may be between 5 to 15% 
depending on the series. However, it has been manifested as albuminuria or proteinuria 
may be present up to 30% in some cohorts of HIV-infected patients (Szczech et al, 2002). 
The prevalence of renal histological involvement has ranged from 1-15% depending on 
the different autopsy series (Shahinian et al, 2000). Patients with HIV infection may 
develop different types of glomerular diseases, vascular lesions and tubulointerstitial 
nephritis related in some cases with the virus itself or other co-infections (Williams et al, 
1998). 
In this chapter we will review at different types of glomerular diseases found in patients 
with HIV infection, highlighting its etipopatogenia, clinical presentation, diagnosis and 
therapeutic alternatives. 
2. Glomerular diseases in patients with HIV infection  
Association between HIV infection and renal disease was first described in 1984, shortly 
after isolation of the virus (Rao et al, 1984). The glomerular diseases are relatively common 
complication in patients infected with HIV, with a wide range of clinical presentations and 
with a poor prognosis in most cases. Although HIV-associated nephropathy (HIVAN) has 
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been considered the most frequent and most representative glomerular disease, after the 
generalized treatment of HIV-infected patients with HAART therapy has allowed the 
emergence of other glomerular diseases with a higher incidence than the general 
population, see Table 1. 
 
 
 HIVAN 
 HIV-Associated glomerulonephritis. Immune complex glomerulonephritis 
 Membranoproliferative glomerulonephritis 
 Membranous nephropathy 
 Mesangial glomerulonephritis (IgA) 
 Focal segmental glomerulosclerosis non-collapsing 
 Lupus-like glomerulonephritis 
 Postinfectious glomerulonephritis 
 Other nephropathies 
 Thrombotic Microangiopathy 
 Malignant hypertension 
 Amyloidosis 
 
Table 1. Glomerular diseases in patients with HIV infection 
2.1 HIV-associated nephropathy  
This type of glomerular disease is HIV-associated nephropathy best described (Rao et al, 
1987). The disease affects mostly males, intravenous drugs users and black patients (D’Agati 
& Appel, 1997). U.S. is the third leading cause of end-stage renal disease (ESRD) in African 
Americans between 20 and 64 years of age and the most common cause of ESRD in HIV-1 
seropositive patients (Eggers & Kimmel, 2004; Shahinian et al, 2000). Prevalence is variable, 
ranging from 4% in clinical studies and 10% in autopsy (Mazbar et al, 1989). Although these 
renal findings can be seen in patients with asymptomatic or primary HIV infection, most of 
patients have low CD4 cells count and advanced disease. 
Among the specific mechanisms involved, in addition to genetic susceptibility (several 
polymorphisms that influence susceptibility to HIV infection), the virus can be seen in 
glomerular epithelial cells (Kimmel et al, 1993; Röling et al, 2006). Transgenic mice were crated 
with HIV-DNA construct inserted into the genome and developed a histological picture and 
clinical presentation very similar to that of humans (Bruggeman et al, 1997). The viral genome 
is detected in different renal structures (tubular cells, podocytes, glomerular parietal epithelial 
cells), even in cases without renal involvement, indicating that the presence in the renal tissue 
is not sufficient to cause nephropathy (Lu & Ross, 2005; Mikulak & Singhal, 2010). There are 
many mediators and the expression of nonstructural viral proteins, cytokines and growth 
factors can modulate and amplify renal injury. The mechanism of viral entry into renal 
epithelial cell is still unknown. CCR5 and CXCR4 are coreceptors to CD4 that mediate HIV-1 
entry into lymphocytes. These receptors have not been demonstrated on renal epithelial cells 
in vivo (Eitner et al, 2000). Recently, have been described the DEC-205 receptor, which 
facilitates the entry of the virus in renal tubular cells (Hatsukari et al 2007). 
HIVAN is a characterized by a constellation of pathologic findings involving glomerular, 
tubular and interstitial compartments. Glomerular pathologic findings include a collapsing 
www.intechopen.com
 
Glomerular Pathology in Patients with HIV Infection 
 
191 
focal segmental glomerulonephritis, with a marked retraction of glomerular capillary loops, 
and occlusion of the lumen (D’Agati & Appel, 1998). Podocytes show intense hypertrophy 
and hyperplasia, which is associated with decrease expression of podocyte maturity 
markers and accumulations of protein in their cytoplasm. On the other hand, there is a 
characteristic intense tubulointerstitial involvement, which gives it a matter of some 
exclusivity over other nephrotic syndromes. These changes consist of dilatation of the renal 
tubules, which sometimes are proliferative microcyst, and large proteinaceous cylinders in 
light, cell infiltrates and areas of fibrosis (D’Agati & Appel, 1998; Klotman, 1999). 
Immunofluorescence usually shows mesangial deposits of IgM and C3 and electron 
microscopy, are frequently observed tubuloreticular inclusions in the cytoplasm of 
endothelial cells. These structures are synthesized by the stimulation of alpha-interferon, as 
in the cases of patients with lupus nephritis. The histological differential diagnoses of focal 
segmental glomerulosclerosis are the collapsing nephropathy heroin abuse, caused by 
bisphosphonates, interferon or parvovirus (Klotman, 1999). 
Main manifestation of HIV-associated nephropathy is a nephrotic syndrome (Herman & 
Klotman, 1998). However, although the proteinuric can be massive in many cases (more 
than 8-10 g/24 h), most patients with HIVAN do not have significant peripheral edema. 
Moreover, patients with HIVAN are usually not hypertensive, a remarkable finding 
considering that more than 90% of black patients with renal insufficiency of other causes 
exhibit hypertension. The kidneys are usually normal in size or larger. Most patients also 
have advanced renal failure at the time of diagnosis.  
Evolution without HAART is poor, with rapid development of renal failure requiring 
dialysis within the first year of diagnosis, and with a high mortality (Winston et al, 1998). 
The beneficial effects of HAART on HIVAN have been shown in individual clinical 
observations. There are reports of resolution of renal disease with the administration of 
HAART, with a recurrence of renal disease after stopping treatment (Scialla et al, 2007). 
Although no controlled clinical trials have demonstrated the effectiveness of any therapeutic 
measure in the HIVAN, it is recognized that HAART prevents or reduces the risk of 
developing HIVAN and if this occurs, the patients may have a slower course and lower 
mortality than in untreated patients (Lucas et al, 2004). Another treatment option is 
recommended in these patients using drugs that blocker renin-angiotensin-aldosterone 
system (BRAAS). These drugs are a part like any other chronic proteinuric nephropathy 
(Wei et al, 2003). Some studies have shown a decrease in proteinuria and a trend towards 
stabilization of renal damage in patients with HIVAN treated with corticosteroids. 
However, this treatment was not without significant side effects (Smith et al, 1994), so it 
should be limited to cases in which treatment with HAART have not produced any 
improvement and if we rule out opportunistic infections. Finally, we can find some curious 
case of spontaneous improvement of the glomerular pathology (Morales et al, 2002). The 
indications for renal replacement therapy with dialysis or transplantation in patients with 
HIVAN are similar to those followed in other chronic renal disease in the general 
population. 
2.2 Immune-mediated glomerulonephritis 
Patients with HIV infection have a higher incidence of other glomerulonephritis whose 
pathogenesis is generally attributed to glomerular deposition of immune complexes (Balow, 
2005; Nochy et al, 1993), see Table 2.  
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 City/Country
Number 
of patients
Gender 
(M/F) 
HCV 
(+)%
Race 
Types of Glomerular 
diseases 
Ref 
Williams DI 
et al 
London 17 
13 M,  
4 F 
 
47% blacks    53% 
caucasians 
HIVAN 41%, MN 23%, 
HUS 12%, others 24 % 
9 
Rao TKS  
et al. 
Nueva York 55 
49 M,   
6 F 
 100% blacks 
HIVAN 90%, Mesangial 
GN 10% 
11 
Mazbar SA 
et al. 
San Francisco 27 
26 M,   
1 F 
 
63% blacks    37% 
caucasians 
HIVAN 27%, MPGN 27%, 
Interstitial nephritis 9%, 
immune complex GN 
with  IgG-IgM 9%, 28 % 
others 
15 
NocheD  
et al. 
Paris 60 
51 M,   
9 F 
 
48% blacks    52% 
caucasians 
43 % HIVAN, Immune 
complex GN 37%, lupus 
like nephritis 16%, HUS 
11.5% 
33 
Casanova S 
et al. 
Italy 26 
21 M,   
5 F 
 100% caucasians
Immune complex GN 
65.5%, MPGN 15.5%, 
lupus like nephritis 
11.5%, minimal change 
7.5% 
34 
Connolly JO 
et al. 
London 34 
25 M,   
9 F 
 
55.8% blacks 
41.1%caucasians
50 % HIVAN,  
14.5 % MN,  
6% MPGN, 12 % HUS, 3% 
Immune complex GN, 
14.5 % others 
53 
Shahinian V 
et al. 
Texas 389 
362 M, 
27 F 
 
54 % blacks   35% 
caucasians 
26%  unknown,  
7 % HIVAN,  
7% immune complex GN, 
17 % ATN,  
25% crystal induced 
nephropathy 
14 
Szczech La 
et al. 
EEUU 89 
73 M,  
16 F 
 
88% blacks   12% 
others 
47% HIVAN,  
53 % non-HIVAN 
6 
Cheng JT  
et al. 
EEUU 14 
8 M,     
6 F 
100 
93% blacks     7% 
caucasians 
79% MPGN, 21% MN 36 
Stokes MB 
et al. 
EEUU 12 
11 M,   
1 F 
100 
58% blacks   42% 
caucasians 
41% MPGN,  
41 % mesangial GN, 8% 
MN, 8 % HIVAN 
37 
Gutiérrez  
et al. 
Madrid, Spain 27 
23 M, 
4 F 
77.8
11% blacks 
89%   caucasians
29.6% MPGN, 25.9% Non-
collapsing FSGS, 22.2% 
mesangial GN, 14.8% 
HIVAN. 
45 
Table 2. Different studies with renal disease in HIV patients 
In Europe, especially in Caucasians, glomerular immune complex glomerular diseases are 
more common than HIVAN and may take several forms. The immune-mediated 
glomerulonephritis would be the counterpart among the white population to what is 
represented by the HIVAN in the black (Casanova et al, 1995).  
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The pathogenesis of these types of glomerulonephritis remains largely unknown; there is 
a local formation or glomerular deposition of circulating immune complexes that may 
contain HIV antigens and polyclonal antibodies. We can not rule out the involvement of 
an immune response against associated viral infections. The clinical features are very 
striking (gross hematuria, edema, acute renal failure, and hypertension), although cases of 
more subtle presentation and are diagnosed incidentally, see Table 3. 
Hypergammaglobulinemia is common, reflecting a polyclonal B cell activation. However, 
the role of some viral co-infections very frequent among HIV patients, such hepatitis C 
(HCV) and hepatitis B virus (HBV), appears to be decisive, particularly in MPGN and 
NM.  
Very limited information is presently available regarding treatment and clinical outcomes in 
patients with immune-mediated GN in patients with HIV infection. Until now we have not 
information about the therapeutic interventions used in patients without HIV infection 
(steroids, immunosuppressants, calcineurin inhibitors) can change the course of immune-
complex glomerulonephritis. 
 
 HIVAN MPGN IgAN 
FSGS-
NC 
MN PIGN
Lupus-
like 
Amyloidosis MAT 
Nephrotic 
syndrome 
4 3 0 3 4 1 4 4 1 
Macroscopic 
hematuria 
0 2 4 0 0 3 2 0 2 
Acute renal failure 1 1 2 1 1 3 1 1 4 
Hypertension/ 
Malignant 
hypertension 
1 1 3 1 1 1 1 0 3 
Hypo-
complementemia 
0 3 0 0 0 4 1 0 0 
Cryglobulins (+) 0 3 0 0 0 1 1 0 0 
Coinfection 
HCV/HBV 
0 4 1 1 2 0 2 1 0 
Treatment 
HAART 
BSRAA
 S 
BSRAA 
VHC (+) 
(INF+RBV)
(S+PF+RTX) 
BSRAA BSRAA
BSRAA 
Several 
clinical 
(S+IMS)
BSRAA
Several 
clinical 
(S) 
HAART
S 
HAART 
Secondary 
aetiology 
Plasma 
P 
HIVAN: HIV-associated nephropathy; MPGN: membranoproliferative GN; IgAN: IgA nephropathy; 
FSGS-NC: Not collapsing forms of FSG; MN: membranous nephropathy; PIGN: Postinfectious GN; 
MAT: Thrombotic microangiopathy; HAART: Highly active antiretroviral therapy; BSRAA: Blockers of 
the system renin-angiotensin-aldosterone; S: steroids; INF: interferon; RBV: ribavirin; RTX: rituximab; 
P:Plasmapheresis. Degrees: (0-4): (Never-Always) 
Table 3. Most common presentations and laboratory markers in glomerular diseases in 
patients with HIV infection 
www.intechopen.com
 
An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
194 
2.2.1 Membranoproliferative glomerulonephritis 
The most common clinical presentation is nephrotic syndrome with macroscopic 
hematuria or microhematuria and normal renal function or mild renal function 
impairment. Up to 90% of cases there are co-infected with HCV (Morales et al, 1997; 
Cheng et al, 1999). Cryoglobulins are detected in most cases with elevated rheumatoid 
factor and decrease of complement, especially C4. The clinical and serological profile is 
very similar to the membranoproliferative GN associated with HCV patients without HIV 
infection. For all these reasons it is considered that this is a pathogenetically GN induced 
by HCV, without the concomitant presence of HIV play a prominent role (Stokes et al, 
1997). 
In some cases the extrarenal manifestations of cryoglobulinemia include clinical 
presentation, with vasculitis cutaneous, and even gastrointestinal manifestations alveolar 
hemorrhage. In these cases we can find an acute renal failure with hematuria and 
proteinuria, and characteristic histological finding of membranoproliferative GN with 
deposits of cryoglobulins in glomerular capillary lumens. Cryoglobulins are usually of a 
mixed IgG-IgM. 
The safety and efficacy of HCV treatment with interferon and ribavirin in patients 
coinfected with HIV has been evaluated in numerous series in the literature (Kadan & Talal, 
2007). There are series of cases in which an effective antiviral treatment correlated with 
improvement in renal manifestations (Kamar et al, 2006). However, we find cases in which 
there is no negativity of cryoglobulins despite the negativity of HCV-RNA, and can even 
clinical manifestations (Morales et al, 2007). There are cases in which clinical aggressiveness 
may be amenable to immunosuppressive treatment. High-dose steroids and plasmapheresis 
may improve the clinical course, although has increased HCV replication and risk of 
worsening liver disease. Rituximab is an anti-CD20 monoclonal antibody that has produced 
a prolonged improvement of renal manifestations in cases that can not be eradicated HCV 
(Kamar et al, 2006).  
In cases of membranoproliferative GN is not associated with HCV; the experience is limited 
and can recommend the use of drugs that block the RAAS, since its effect antiproteinuric, 
renoprotective and antihypertensive. 
2.2.2 IgA nephropathy 
Series have described several cases of IgA nephropathy in patients infected with HIV. The 
actual incidence is unknown, but in a study of 116 autopsies in patients with HIV infection 
were detected IgA glomerular deposits by 7.7% (Beaufils et al, 1995).  
Patients infected with HIV develop IgA antibodies against specific HIV antigens and this 
seems to be the pathogenic basis of this nephropathy. On the other hand, can produce 
idiotype IgA antibodies against other antibodies IgG and IgM directed against viral 
antigens. Renal lesions may result from HIV antigen-specific immune complexes that are 
derived from the circulation and from in situ complex formation (Kimmel et al, 1992). 
Clinical presentation is similar to that of idiopathic IgA nephropathy: microhematuria with 
occasional episode of gross hematuria after infection mainly located in the upper respiratory 
tract and different proteinuria degrees. The long-term prognosis depends mainly on the 
amount of the proteinuria. In addition to these developments chronic, slowly progressive, 
characteristic of IgA nephropathy, patients may also develop acute complications similar to 
those of the IgA idiopathic acute renal failure that is associated with macroscopic hematuria 
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is a widely known complication (Gutierrez et al, 2007) and development of hypertension 
malignant (MHT) (Chen et al, 2005). In episodes of gross hematuria may develop acute 
tubular necrosis, tubular abnormalities consist in a high proportion of tubules that are filled 
by red blood cells (RBC) casts and signs of tubular necrosis that are more evident in tubules 
that are occupied by RBC casts, see Figure 1. 
 
 
Fig. 1. Tubules filled by red blood cells, showing diminished number of lining epithelial 
cells and nuclear pyknosis.  
Regarding the MHT, is observed in a significant percentage (5% -7%) of cases of idiopathic 
IgA, but some series indicate that its incidence may be even higher in HIV-associated IgA 
nephropathy. In our experience, most of the cases with HIV-infection and IgA nephropathy 
presented malignant hypertension (Gutierrez et al, 2007). The prognosis is poor and many 
cases progress to irreversible end-stage renal failure, see Figure 2. However, in some 
patients the effective control of blood pressure drug type inhibitors of angiotensin 
converting enzyme (ACE) inhibitors and / or antagonists of the angiotensin receptor (ARB) 
manages to partially reverse renal failure. 
In some patients with HIV infection, as also in Idiopathic IgA renal manifestations may be 
associated with systemic manifestations of the type of vasculitis cutaneous, arthritis and 
various digestive disorders, all components of the Schönlein-Henoch syndrome. 
At the present there is a little information about the treatment and outcomes of patients with 
HIV infection. Therefore, according to the recommendations in idiopathic IgA, it is 
recommended to treat all patients who develop significant proteinuria (>0.5-1 g / day) or 
hypertension, with ACE inhibitors or ARB, since the antiproteinuric and renoprotective 
effect of these drugs, also tested with IgA nephropathy (Praga et al, 2003). 
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Fig. 2. Renal survival of patients with mesangial IgA nephropathy and MHT and mesangial 
nephropathy patients without MHT. 
2.2.3 Focal segmental glomerulosclerosis non-collapsing 
Among the different histological forms of focal glomerulosclerosis, have also been reported 
not collapsing glomerulosclerosis in patients with HIV (Haas et al, 2005). The pathogenesis 
and the exact relationship of these GN may have HIV or other pathogens have not been 
investigated.  
Very limited information is available about the real incidence, clinical and developmental 
characteristics and therapeutic possibilities of this entity. In our experience, this type of 
glomerular disease is the second most common presentation in our HIV-infected patients 
(Gutierrez et al, 2007). The most common clinical presentation was proteinuria, and 
nephrotic syndrome was observed in 72% of cases. All patients were treated with HAART 
and BSRAA; at the end of treatment no patient need dialysis and 60% had renal 
insufficiency (Gutierrez et al, 2007).  
In idiopathic forms, not associated with HIV, proteinuria and nephrotic syndrome are 
common manifestations. Some cases progress rapidly to ESRD. Corticosteroids administered 
for a long time for months and calcineurin inhibitors drugs are treatment options supported by 
experience. However, given the absence of data on HIV-infected patients and the susceptibility 
of these patients to infections, careful observational studies are needed before recommending 
these options. The optimization of antihypertensive and antiproteinuric drugs (ACEI/ARB) 
can exert a favorable effect, as in idiopathic less aggressive forms. 
2.2.4 Membranous nephropathy 
Membranous nephropathy (MN) is a typical example of glomerular disease mediated by 
deposition of immune complexes. MN is a recognized complication of renal malignancies 
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and infections. Among these, HBV and HCV have been associated with the development of 
MN and syphilis, and various parasitic diseases. 
In this context, the frequent presence of HBV and HCV co-infection and the increasing 
incidence of syphilis and other infectious processes suggests that there may be a 
predisposition of patients with HIV infection to the development of MN, although not 
known actual incidence and its outcome. 
The characteristic clinical presentation is nephrotic syndrome, although minorities of cases 
show no nephrotic range proteinuria. In forms idiopathic, there are two therapeutic 
strategies that have proven effective in controlled prospective studies, immunosuppression 
with steroids plus cyclophosphamide or chlorambucil, and calcineurin inhibitors drugs 
(cyclosporine, tacrolimus) (Praga, 2008). However, consider that a high percentage (up to 
50% in some series) have spontaneous remission within the first years of the disease 
(Polanco et al, 2010) for this reason may be preferable initially attitude conservative in 
patients with HIV-infection. All chronic proteinuric nephropathies may be beneficial to use 
renin-angiotensin-aldosterone system blockers (ACEI/ARB). If we can identify an infectious 
agent as pathogenic factor, the treatment could potentially resolve the kidney problem. 
2.2.5 Postinfectious glomerulonephritis 
Although the descriptions are limited (Enriquez et al, 2004), patients with HIV infection 
could be theoretically exposed to the development of postinfectious GN due to its higher 
rate of infection. The clinical picture is generally abrupt, with hypertension difficult to 
control, often gross hematuria and mild and transient impairment of renal function 
frequently. There are typical red blood cell casts present in urinary sediment and 
hypocomplementemia. Renal biopsy shows a diffuse endocapillary GN with proliferation of 
mesangial and endothelial cells, Glomerular and interstitial infiltration of monocytes and 
lymphocytes is present. Glomerular accumulation of neutrophils is common and is termed 
“exudative”. Ultrastructural studies demonstrate the subepithelial “humps” which are 
typical although not pathognomonic of postinfectious GN.  
The history of an infection, usually 1-2 weeks, followed by a short asymptomatic period and 
the typical abrupt onset of nephritic syndrome for the diagnosis in many cases, along with 
the study of the sediment and the detection of hypocomplementemia. The majority of cases 
have benign course with conservative treatment of the infectious process and complications 
(hypertension, edema). The descriptions of acute postinfectious GN in patients with 
endocarditis or localized infections are characteristic, although they have published very 
few cases among HIV-infected patients. 
2.2.6 Lupus-like glomerulonephritis 
Lupus-like glomerulonephritis, defined by the presence of a “full house” of glomerular 
immunoglobulin and complement deposits on immunofluorescence in the absence of 
serologic evidence of systemic lupus erythematosus (SLE). There is presently little 
information known about the etiology, its treatment, or its long-term outcome. 
Its main histological features are cell proliferation and mesangial matrix, the presence of 
hyaline thrombi and massive deposit of immune complexes in capillary walls, which reach 
mimic the "wire loops" typical of lupus nephritis and are the origin of name ("lupus-like") 
that has been proposed for these cases. In immunofluorescence, as occurs in lupus nephritis, 
deposit detects all types of immunoglobulins (IgG, IgA, IgM) and various fractions of 
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complement (Haas et al, 2005; Weiner et al, 2003). However, the term may be misleading, 
because the similarities end with lupus in the histological aspects of renal biopsy. There are 
no systemic symptoms similar to lupus flares and serology (ANA and anti-DNA, 
hypocomplementemia) is negative. 
Most reported cases present with nephrotic syndrome and progressive deterioration of 
renal function. No information about the natural history of this process and whether or 
not modify therapeutic interventions. Regarding the pathogenesis, there are only 
speculations. It is proposed that, in addition to frequent infections with HBV, HCV and 
other infectious agents, HIV itself through several of its proteins (p24, gp41, gp120) can 
induce a systemic response of immunoglobulin, causing a large amount of circulating 
immune complexes that would be trapped nonspecifically in the glomerulus, 
alternatively, the HIV proteins could be initially deposited in the glomerulus (planted 
antigens) and subsequently be detected by the antibody in situ formation of immune 
complexes (Weiner et al, 2003). 
Although we can be exceptionally patient with HIV infection and the coexistence of lupus 
with renal involvement, and it would be important to make a diagnosis difference between 
the two entities. In patients with both HIV infection and a diagnosis of SLE, three patterns of 
disease occurrence have been described: HIV following SLE diagnosis, SLE following HIV 
infection, and simultaneous diagnosis of HIV and SLE. Since the appearance of an 
autoimmune disorder in patients with a pre-existing immunodeficiency would not be 
expected, at least from a mechanistic standpoint, we will focus our review on patients with 
existing HIV who developed signs and symptoms consistent with a new diagnosis of lupus. 
SLE and HIV infection are two diseases whose clinical and serologic presentations may 
occasionally mimic one another, but with pathogenic mechanisms that theoretically are 
mutually exclusive. The seemingly paradoxical coexistence of these two immune disorders 
offers intriguing insights into the complex cellular and humoral immune networks that 
govern autoimmune phenomena and self tolerance. 
Finally, the clinical management of the HIV positive lupus patient represents a therapeutic 
challenge for the physician due to the delicate equilibrium that needs to be achieved 
between SLE remission and HIV control (Gindea et al, 2010). 
2.3 Other nephropathies in patients with HIV infection 
2.3.1 Thrombotic microangiopathy 
Thrombotic microangiopathy (TMA) is a known complication of HIV infection (Connolly et 
al, 1995; Alpers, 2003). Published reports of the incidence of TMA evaluated during the pre-
HAART era vary considerably, depending on the type of study performed, diagnostic 
criteria used to evaluate patients, and stage of HIV disease (Connolly et al, 1995). It is likely 
that this under-diagnosed entity, as shown in autopsy studies (Gadallah et al, 1996) and 
patients with progressive deterioration of renal function, the presence of MAT in renal 
biopsy exceeded the incidence of HIVAN (Peraldi et al, 1999). 
Endothelial cell injury appears to be the primary event causing platelet activation and 
deposition in the microvasculature. On these microthrombi mechanical destruction would 
occur, anemia, schistocytes, elevated LDH and Coombs test negative. Direct cytopathic 
roles of HIV as well as other factors such as malignancy, drugs, and infectious agents 
have been implicated in the pathogenesis of HIV-TMA. It is known that various HIV 
proteins can directly damage endothelial cells, inducing apoptosis therein (Alpers, 2003). 
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In experimental animals infected with HIV often develops MAT, so it is suspected that 
HIV itself plays a key role in endothelial damage (Eitner et al, 1999). It is also the 
possibility that anticardiolipin antibodies/antiphospholipid frequently detected in HIV 
patients (Boue et al, 1990) have pathogenic importance. In the primary antiphospholipid 
syndrome or lupus erythematosus associated with MAT may be triggered. Although not 
able to demonstrate that HIV-infected patients with anticardiolipin antibodies are at 
higher risk for MAT, it is an intriguing association. In idiopathic MAT has been achieved 
in many cases to elucidate the molecular basis of the disorder, especially those with 
family history: gaps ADAMS-13 and other enzymes that degrade the von Willebrand 
factor in type forms PTT and alterations of the complement system in the SHU. There is 
no evidence that these disorders occur in the MAT of patients infected with HIV. 
Although the majority of patients present in a more advanced stage of HIV disease, TMA 
can be the initial presenting symptom of HIV infection.  
Clinical features are those of idiopathic TMA (Eitner et al, 1999), and the diagnosis should 
be suspected in any patient with new onset thrombocytopenia and microangiopathic 
haemolytic anaemia. Most patients are male and young and progressive deterioration of 
renal function is associated with the typical hematological findings MAT: schistocytes 
anemia with peripheral blood, thrombocytopenia, elevated LDH. Although most cases 
present a clear and rapidly progressive deterioration of renal function, similar to pictures of 
hemolytic uremic syndrome (HUS), others can have predominant neurologic manifestations, 
as in thrombotic thrombocytopenic purpura (TTP). 
Kidney biopsy shows changes similar to idiopathic MAT: platelet-fibrin thrombi in 
preglomerular arterioles and the glomerular capillaries, arterioles with endothelial edema 
imaging in "onion skin" and mesangiolysis with widening of subendothelial space. When 
there are extrarenal manifestations (neurological, cardiac) vascular lesions are similar in the 
vessels of the affected organs. 
Therapy with plasma exchange or infusion appears to be efficacious. A rapid diagnosis and 
institution of plasmapheresis is crucial for a favorable outcome. The long term prognosis of 
HIV-TMA is unfavorable and may depend on the stage of HIV infection. The recent data 
after the use of highly active retroviral treatment, however, are unavailable and current 
prognosis is therefore uncertain.  
2.3.2 Malignant hypertension 
Malignant hypertension is defined by the presence of unacceptably high blood pressure 
with grade III hypertensive retinopathy (hemorrhages and exudates) or IV (papilledema 
more vascular lesions). As we noted earlier, is a casual presentation of idiopathic IgA 
nephropathy, but its impact on the rest of idiopathic GN is rare. By contrast, preliminary 
studies indicate incidence of MHT special not only in IgA nephropathy patients with HIV, 
in which may be the most frequent presentation of this entity, but in other glomerular 
diseases associated with HIV (Morales et al, 2008). On the other hand, entities such as 
membranoproliferative GN, membranous and focal glomerulosclerosis, in which the MHT 
is a rare complication, there are a significant number of cases when associated with HIV 
infection. In our experience, malignant nephrosclerosis (arteriolar fibrinoid necrosis with 
intimal thickening and luminal narrowing; see Figure 3) was detected in six cases (three of 
them with IgAN, one with C-FSG, one with NC-FSG and one with MGN). 
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Fig. 3. Renal biopsy of patient 1 (Table 1), showing a glomerulus with mesangial 
proliferation (the immunofluorescence showed predominant deposits of IgA) and vascular 
lesions of malignant nephrosclerosis (fibrinoid necrosis) in the afferent arteriole. 
(hematoxylin;eosin; x400). 
The typical symptoms of MHT (markedly increased BP, blurred vision due to retinal 
haemorrhages and severe headache). To interpret this catastrophic prognosis in HIV 
patients with GN and MHT, we speculate that the development of MHT has an irreversible 
detrimental influence on glomerular diseases already having a rather poor prognosis by 
themselves, see Figure 4.  
On the other hand, the development of chronic renal failure could likely exacerbate the 
appearance of infectious and cardiovascular complications in these HIV-infected patients 
because both patients with chronic renal failure and HIV infection are particularly prone to 
the appearance of such complications (Grinspoon & Carr, 2005; Kamin & Grinspoon, 2005; 
Gupta et al, 2005). Other possible pathogenic pathways to explain this particular propensity 
of HIV patients with glomerular diseases to MHT could rely on the already known higher 
incidence of thrombotic microangiopathy (TMA) among HIV patients (Alpers, 2003). Both 
TMA and MHT could be interpreted as clinical manifestations of a systemic endothelial 
injury, due to a direct toxic effect of HIV, other infectious agents (particularly HCV and 
HBV) or other factors (such as drug addictions) linked to the environment of HIV infection. 
On the other hand, the presence of antiphospholipid antibodies is also more common 
among HIV patients, and these autoantibodies could play a role in endothelial vascular 
damage (Alpers, 2003; Galrao et al, 2007).  
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Fig. 4. Probability of renal survival (absence of chronic dialysis) in HIV patients with or 
without malignant hypertension. 
In addition, considering the dismal prognosis of our patients in spite of HAART treatment 
and a satisfactory control of blood pressure, early detection and treatment of hypertension 
in HIV patients with glomerular diseases are mandatory. 
2.3.3 Amyloidosis 
In autopsy series of patients infected with HIV, as well as reviews of renal biopsies, 
amyloidosis is a relatively common finding (Lanjewar et al, 1999; Joseph et al, 2000). This is 
a secondary amyloidosis, type AA. Many studies have been suggested that frequent chronic 
infections may be responsible for this complication. However, it is possible that HIV 
infection itself plays a pathogenic role. Described a high level of SAA, acute phase reactant 
which is the precursor of AA amyloid in patients infected with HIV (Husebekk et al, 1986) 
and experimental models have shown that a significant proportion of animals infected 
develop amyloidosis (King et al, 1983). 
As is common in amyloidosis, massive proteinuria and nephrotic syndrome were the most 
common renal manifestations in the cases described. There are no studies about specific 
therapeutic options in these patients, apart from trying to eradicate the underlying 
infectious process. 
2.3.4 Hypertensive and diabetic nephropathy 
Metabolic complications of HAART (dyslipidemia, changes in body fat, insulin resistance, 
diabetes mellitus) and the aging of the infected population suggest that kidney damage 
secondary to diabetes and hypertension may have increasing importance in patients 
infected HIV (Masia-Canuto et al, 2006).  
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In some series of renal biopsies of patients with HIV infection has been reported the 
presence of diabetic nephropathy in 6% of cases, hypertensive nephropathy in 4% (Szczech 
et al, 2004).The recommended treatment is similar to that used in the uninfected population 
and should include strict control of blood pressure and the early use of BSRAA to try to 
reduce proteinuria. 
3. Tubular and interstitial renal disease 
Patients infected with HIV can present a wide variety of tubular and interstitial renal 
disease secondary to drugs, infections and/or tumors; see Table 4 (GESIDA, 2010; Blok & 
Weening, 1999). 
 
 
 Acute tubular necrosis 
 Interstitial nephritis associated with drugs 
 Renal failure and Fanconi syndrome (certain reverse transcriptase inhibitors) 
 Allergic interstitial nephritis 
 Cristal-induced nephropathy (certain protease inhibitors) 
 Interstitial nephritis associated with infections (cytomegalovirus, tuberculosis, hongos, 
Salmonella, Legionella, etc) 
 Kaposi sarcoma and Lymphoma infiltrative 
 Rhabdomyolysis 
 
Table 4. Tubular and interstitial renal disease 
The recommendations for the treatment of these nephropathies consist of drug withdrawal 
or correction of the precipitating cause, corrections, electrolyte, and in interstitial nephritis 
immunoallergic the administration of a short course of corticosteroids. 
4. Conclusion  
In conclusion, due to the wide range of kidney damage in people with HIV infection, it is 
difficult to predict the renal histology according to clinical criteria, so renal biopsy is 
mandatory for histologic diagnosis. In addition, the course and prognosis of these patients 
has changed radically since the introduction of antiretroviral therapy, with higher survival, 
so early diagnosis is essential and the establishment of an alternative therapy to prevent 
progression of renal disease. 
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